Panuveitis and dermal vasculitis following MMR vaccination.
Sedaghat
M
M
Khatam-Al-Anbia Eye Hospital, Mashad University of Medical Sciences, Mashhad, Islamic Republic of Iran. sizagh@yahoo.com
Zarei-Ghanavati
S
S
Shokoohi
S
S
Ghasemi
A
A
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001706:Biopsy; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D016903:Drug Monitoring; D005260:Female; D005334:Fever / Q000139:chemically induced; D005451:Fluorescein Angiography; D006801:Humans; D007492:Iran; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects*; D008775:Methylprednisolone / Q000627:therapeutic use; D009887:Ophthalmoscopy; D015864:Panuveitis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D015985:Precipitating Factors; D014657:Vasculitis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D014792:Visual Acuity
D000893:Anti-Inflammatory Agents; D022542:Measles-Mumps-Rubella Vaccine; D008775:Methylprednisolone